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Summary. Background: Recent reports have suggested an
association of atherosclerosis with risk of venous thrombosis.
Objective: To conﬁrm whether subclinical atherosclerosis is a
risk factor for venous thrombosis (VT) amongmen andwomen
age 65 and older.Methods: Participants of the Cardiovascular
Health Study (n ¼ 4108) without baseline clinical cardiovas-
cular disease, anticoagulant use or previous VT were followed
for a median of 11.7 years after non-invasive assessment of
subclinical atherosclerosis using carotid ultrasound (intima-
media thickness and presence of plaques), ankle-brachial blood
pressure index and electrocardiogram.Each eventwas classiﬁed
as idiopathic or secondary. We used Cox proportional hazards
regression to estimate the relative risk of overall and idiopathic
VT for individuals with and without baseline subclinical
atherosclerosis. Results: There were 133 ﬁrst time VT events.
No subclinical atherosclerosis measures were associated with
increased risk of overall or idiopathic VT. The adjusted relative
risks of overall and idiopathic VT for presence of any type of
subclinical disease were 0.60 (95% conﬁdence interval 0.39–
0.91) and 0.32 (0.18–0.59), respectively.Most of this association
was explained by an inverse association of high-risk carotid
plaques (prevalent in 54%of those at risk)withVT.Conclusion:
Non-invasively measured subclinical atherosclerosis was not
associatedwith increased risk of overall or idiopathic VT in this
observational study. Carotid plaques and arterial events during
follow up were inversely associated, a ﬁnding that requires
further study.
Keywords: atherosclerosis, deep vein thrombosis, pulmonary
embolism, risk factor.
Venous thrombosis affects 1–3 per 1000 adults each year in
developed countries [1–5]. It is the third most common
cardiovascular disease in the USA [6]. It is most commonly
manifested in the deep veins of the leg or as a pulmonary
embolism (PE); both fall under the broader term venous
thrombosis (VT).
Although VT shares some risk factors with atherosclerosis,
such as older age, male sex, and obesity, little information is
available about whether the presence of atherosclerosis, at
Correspondence: Mary Cushman, Departments of Medicine and
Pathology, University of Vermont, 208 South Park Drive, Suite 2,
Colchester, Vermont 05446, VT, USA.
Tel.: +1 802 656 8968; fax: +1 802 656 8965; e-mail: mary.cushman@
uvm.edu
Received 20 April 2006, accepted 12 June 2006
Journal of Thrombosis and Haemostasis, 4: 1903–1908
 2006 International Society on Thrombosis and Haemostasis
either a subclinical or a clinical level, is associated with
increased risk of VT.
Classical atherosclerotic risk factors, such as hypertension,
hyperlipidemia and smoking are not considered risk factors for
VT, so it would seem unlikely that atherosclerotic disease
would be related to risk of VT. Less common risk factors such
as hyperhomocysteinemia and antiphospholipid antibodies
appear to relate to both arterial and venous disease [7–9].
A recent study by Prandoni and colleagues [10] reported a
higher frequency of carotid plaques (as an indicator of
atherosclerosis) in patients who had previous idiopathic VT
compared to hospitalized controls. A similar association was
not observed among patients with secondary VT. Further
conﬁrmation of this ﬁnding is not available.
The aim of this study was to examine the association
between non-invasively measured subclinical arterial disease
and the risk of future VT in a population-based cohort study,
the Cardiovascular Health Study (CHS).
Methods
Participants
The CHS is a population-based longitudinal study initially of
5201 adults enrolled in 1989–1990. An additional 687 African-
Americans were recruited 3 years later to increase their repre-
sentation.The studydesignhasbeenpublished [11]. Participants
aged 65 years and older were recruited from four areas in the
USA: Forsyth County, NC; Washington County, MD; Sacra-
mentoCounty,CA; andPittsburgh, PA. Potential subjectswere
excluded if theywere institutionalized,undergoing treatment for
active cancer, planning tomove from the areawithin 2 years, or
unable to give informed consent. Twice yearly follow-up
involved alternating telephone calls and clinic visits. The study
was approved by the institutional review board at each ﬁeld
center, and all participants gave informed consent.
Exclusion criteria for this analysis were prevalent clinical
arterial disease (n ¼ 1570), warfarin use at baseline (n ¼ 98) or
previousVT (n ¼ 354). Therewere 188 participantswith two of
these criteria and 27 with all three. Prevalent clinical arterial
diseasewas deﬁnedas ahistory ofmyocardial infarction, stroke,
claudication, angina, transient ischemic attack, congestive heart
failure, carotid endarterectomy, coronary artery bypass or
angioplasty, or leg artery bypass or angioplasty. These prebase-
line events were conﬁrmed by medical record review.
Definitions
Baseline measures of subclinical atherosclerosis were ankle
brachial index (ABI), internal and common carotid ultrasound
to assess intima-media thickness (IMT) and presence of plaque,
and resting 12-lead electrocardiogram (ECG). All participants
underwent duplicate restingmeasurements of the ankle and arm
blood pressures to calculate the ABI as the ratio of the ankle to
arm systolic blood pressure [12]. High-resolution B-mode
ultrasonography of the carotid arteries was used. Trained
technicians acquired one longitudinal image of the common
carotidarteryand three imagesof the internal carotidartery [13].
Ultrasounds were centrally read as previously described at the
UltrasoundReading Center in Boston,MA,USA [14]. Carotid
plaque, deﬁnedby theappearanceof the largest focal lesion,was
classiﬁed by surface characteristics, echogenicity, and texture.
Surface characteristics were classiﬁed as smooth, mildly irregu-
lar (height variations of 0.4 mm or less), markedly irregular
(height variationsofmore than 0.4 mm), or ulcerated (a discrete
depression of more than 2 mm in width extended into the
media). Lesion echogenicity was characterized as hypoechoic,
isoechoic, hyperechoic, or calciﬁed.Lesion texturewas classiﬁed
as homogeneous or heterogeneous. Plaques were deﬁned in
three groups: absent, intermediate risk, or high risk. Absence of
plaquewas deﬁned as a smooth intimal surfacewith no regional
discrete plaque. Intermediate risk plaques were hyperdense,
calciﬁed or homogeneous plaques, or those with a mildly
irregular surface.High-riskplaqueshadan irregularorulcerated
surface, orwere hypodense orheterogeneousplaques occupying
more than 50% of the total plaque volume. Major ECG
abnormalities were deﬁned as ventricular conduction defect,
major Q-wave abnormalities, left ventricular hypertrophy,
isolated ST-T wave abnormalities, atrial ﬁbrillation, or ﬁrst-
degree atrio-ventricular block [15]. We deﬁned presence of
subclinical atherosclerosis as any one of the following:
ABI < 0.9, maximal internal or common carotid IMT in the
top quintile (internal 1.93 mm for men, 1.68 mm for women;
common 1.23 mm for men, 1.14 mm for women), presence of
carotid plaques, or major ECG abnormalities [15].
Race was categorized based on participant self-report as
white, black, or other. Diabetes was deﬁned by the American
Diabetes Association criteria [16]. Body mass index (BMI) was
used to deﬁne normal weight (BMI < 25 kg m)2), overweight
(BMI 25–30 kg m)2), and obese (BMI > 30 kg m)2) [17].
During the baseline examination fasting glucose and lipid levels
were measured [11]. Aspirin and statin use were assessed at
baseline by medication inventory.
Follow-up
Ascertainment of VT events during follow-up has been
described in detail [18]. All hospitalization data were ascer-
tained based on self-report or the Health Care Financing
Administration Database. If there was an indication of a
possible thrombosis event based on self-report or discharge
diagnosis codes, hospital records were reviewed using stan-
dardized criteria by two physicians to determine whether a VT
had occurred. Deep vein thrombosis (DVT) events required
positive duplex or Doppler ultrasound or venogram, and
occasionally were based on impedance plethysmography. PE
events required positive ventilation-perfusion lung imaging,
computed tomography, or autopsy. Each event was classiﬁed
as idiopathic or secondary (occurring within 90 days of major
trauma, surgery, or marked immobility, or associated with
active cancer or chemotherapy) [18]. Incident VT events that
occurred between baseline and the end of 2001 were included in
these analyses.
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Statistical analysis
Incidence rates of VT during follow-up were calculated in
participants with and without subclinical atherosclerosis at
baseline by dividing the total number of cases by the number of
person-years of observation. The Poisson distribution was used
to calculate 95% conﬁdence intervals (CI) [19]. Cox propor-
tional hazards regression was used to estimate the relative risk
(hazard ratios) of overall and idiopathic VT for individuals
with compared to those without subclinical atherosclerosis.
These analyses were performed for the various types of
subclinical atherosclerosis. We ﬁrst estimated unadjusted
hazard ratios and subsequently adjusted for baseline age, sex,
race, FVIII level and obesity status, which were previously
reported as risk factors for VT in this cohort [17]. Participants
were censored from analyses at the time of death or the end of
follow-up. To assess important subgroups we performed
analyses stratiﬁed by sex, race, baseline obesity status, and
baseline age (above or below 75 years).
Results
The mean age of the 4108 participants at baseline was
72.4 years. About 61% were women, 84% were white and
over 81% had subclinical atherosclerosis. The most common
type of subclinical disease was presence of high-risk carotid
plaques, present in 54% of these elderly participants. Table 1
shows the baseline characteristics based on subclinical disease
status. As expected, atherosclerotic risk factors such as older
age and diabetes were more common among those with
subclinical disease. Statin use at baseline was rare.
There were 133 ﬁrst-time venous thrombosis events; 52
(39%) were idiopathic. Incident VT was more likely with older
age (P ¼ 0.07) and with obesity, but not in the presence of
speciﬁc atherosclerotic risk factors such as hypertension,
increased cholesterol, diabetes and smoking (data not shown).
As shown in Table 2, the incidence rate of overall VT was
lower in participants with compared to without any form of
subclinical atherosclerosis (3.10 and 3.98 per 1000 person-
years). Some forms of subclinical atherosclerosis were associ-
ated with higher incidence of overall VT (ankle-brachial
index < 0.9 and elevated common carotid IMT), while other
forms were associated with lower incidence (presence of carotid
plaques and major ECG abnormalities). For idiopathic VT
similar patterns were generally observed. To further address
carotid IMT, we divided the distribution of IMT into quartiles
for analysis (bottom of Table 2). While the incidence of overall
VT rose across quartiles of common carotid IMT, there was no
such pattern for idiopathic VT, and VT incidence declined
across internal carotid IMT quartiles, particularly for idio-
pathic VT.
In Table 3, Cox proportional-hazard models before and
after adjustment for age, sex, race, FVIII, and obesity status,
suggested that some forms of subclinical atherosclerosis were
associated with a lower risk of VT. For example, the adjusted
hazard ratio of overall VT for high-risk carotid plaques was
0.65 (0.42–1.00), and for major ECG abnormalities was 0.50
(0.27–0.92). For idiopathic VT the inverse associations were
sometimes stronger; the adjusted hazard ratio of idiopathic VT
for elevated internal carotid IMTwas 0.27 (95%CI 0.08–0.87).
Intermediate or high-risk carotid plaques were associated with
more than a 50% lower risk of idiopathic VT; adjusted hazard
ratios were 0.42 (95% CI 0.19–0.96) and 0.34 (0.18–0.65),
respectively. In secondary analyses assessing carotid IMT in
quartiles, the fourth quartile of internal carotid IMT was
associated with a signiﬁcantly lower risk of overall and
idiopathic VT. Among those with any type of subclinical
atherosclerosis, there was a 40% lower risk of overall VT and a
70% lower risk of idiopathic VT. This was largely a reﬂection
of the high prevalence of carotid plaques and their inverse
association with VT.
In an effort to explain the inverse association of atheroscler-
osis with VT, we assessed whether participants with subclinical
atherosclerosis were less likely to be exposed to VT risk
situations by analyzing the incidence of hospitalization overall
or for pneumonia according to quintiles of carotid IMT.
Hospitalizations during follow-up were more common among
those with subclinical disease (data not shown). In addition, we
assessed the occurrence of arterial events during follow-up
prior to a diagnosis of VT (or the end of follow-up for those
without VT), and the risk of VT comparing those with or
without an interim arterial event. The rate of arterial events in
those with or without VT was 21% and 27%, respectively
(P ¼ 0.16). Further the relative risk of VT in those with arterial
events was 0.73 (95%CI 0.48–1.10) before adjustment and 0.62
(0.39–0.98) after adjustment for other risk factors.
Stratiﬁcation of the Cox models for sex, race, obesity status,
aspirin or statin use and age above or below 75 years did not
reveal any differences in associations based on these factors
(data not shown).
Table 1 Baseline characteristics of participants with or without subclinical
disease
Characteristic
Subclinical
atherosclerosis
present (n ¼ 3332)
Subclinical
atherosclerosis
absent (n ¼ 776)
Mean age, years (range) 72.8 (68–76) 70.7 (67–73)
Sex, female 1952 (58.6) 553 (71.3)
Race
White 2786 (83.6) 674 (86.9)
Black 520 (15.6) 99 (12.8)
Other 26 (0.8) 3 (0.4)
Diabetes status
Normal 2334 (70.7) 613 (79.6)
Impaired fasting glucose 460 (13.9) 98 (12.7)
Diabetes 506 (15.3) 59 (7.7)
Body mass index (kg m)2)
< 25 1289 (38.8) 328 (42.5)
25 to < 30 1391 (41.9) 306 (39.6)
‡ 30 643 (19.4) 138 (17.9)
Cancer: ever diagnosed 460 (13.8) 98 (12.6)
Regular aspirin use 936 (28.1) 215 (27.7)
Statin use 58 (1.7) 9 (1.2)
Values are number (%) or mean (interquartile range).
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Discussion
In this cohort study of older men and women without clinical
arterial vascular disease, baseline measurements of subclinical
atherosclerosis, including carotid artery disease, were not
associated with increased risk of VT. Unexpectedly, presence
of some forms of subclinical atherosclerosis, in particular
carotid plaques, was associated with a lower risk of future VT.
An inverse association of arterial disease events during with
follow-up with subsequent VT supports this ﬁnding.
Prandoni and colleagues [10] reported a higher prevalence of
carotid plaques among participants with previous idiopathic
VT compared with hospitalized controls. Their study included
slightly younger subjects (by 5 years) and deﬁned carotid
plaques differently. Regardless, our ﬁndings suggest that bias
or confounding may have played a role in the positive ﬁndings
of that study. Use of hospitalized controls and measurement of
risk factors after hospitalization for VT, not prior to VT as in a
prospective study, may help explain differences in ﬁndings. It is
possible that the plaques observed in the Prandoni study had
more thrombogenic characteristics, thus were more common in
VT patients, however in our study high-risk plaques, which
would be more likely thrombogenic, were inversely associated
with VT risk. In our study, with amedian of 12 years of follow-
up after measurement of subclinical atherosclerosis, we
observed an inverse association of carotid plaques with future
VT, with a stronger inverse relationship for idiopathic
compared to overall VT.
One might argue that the inverse association we observed
betweensomeformsof subclinical atherosclerosis andfutureVT
was due to interventions received after baseline by participants
with subclinical disease (e.g. aspirin, statins, anticoagulants).
However, participants were not informed of subclinical disease
status unless there was severe carotid stenosis, so this seems an
unlikely explanation. It is also possible that the deﬁnition of
carotid plaques used here explains the unexpected ﬁnding;
however associations were similarly inverse in analyses of
internal carotid IMT, a well-validated measure that predicts
future clinical atherosclerotic events. Given the lack of a
hypothesis explaining these associations, it is possible that they
represent a chance ﬁnding and further study is required.
Previous reports showed varying results concerning the
associations of VT with atherosclerotic risk factors such as
cigarette smoking, dyslipidemia, and hypertension, although
most evidence points to the absence of an association [20–24].
The large prospective LITE (Longitudinal Investigation of
Thromboembolism Etiology) cohort, which includes the CHS
cohort, reported no association of any of these cardiovascular
Table 2 Incidence rates per 1000 person-years of venous thromboembolism according to subclinical disease status at baseline, 1989–2001
Characteristic
Incidence rate of all VTE Incidence rate of idiopathic VTE
Cases (n)/at risk (n) Incidence rate 95% CI Cases (n)/at risk (n) Incidence rate 95% CI
ABI
‡ 0.9 115/3640 3.12 2.60, 3.75 46/3640 1.25 0.94, 1.67
< 0.9 12/383 4.03 2.29, 7.09 4/383 1.34 0.50, 3.58
ICA IMT (Sex speciﬁc*)
< 80th percentile 110/3292 3.30 2.74, 3.98 48/3292 1.44 1.08, 1.91
‡ 80th percentile 23/816 3.18 2.12, 4.79 4/816 0.55 0.21, 1.47
CCA IMT (Sex speciﬁc*)
< 80th percentile 107/3317 3.18 2.63, 3.85 45/3317 1.34 1.00, 1.79
‡ 80th percentile 26/791 3.74 2.55, 5.49 7/791 1.01 0.48, 2.11
Major ECG abnormalities
No 109/3103 3.46 2.87, 4.17 44/3103 1.40 1.04, 1.88
Yes 20/884 2.53 1.63, 3.93 8/884 1.01 0.51, 2.03
Carotid plaque risk groups
Absent 40/1000 3.79 2.78, 5.17 23/1000 2.18 1.45, 3.28
Intermediate 25/864 2.92 1.97, 4.32 8/864 0.93 0.47, 1.87
High 67/2220 3.15 2.48, 4.00 21/2220 0.99 0.64, 1.51
Any subclinical atherosclerosis
No 33/776 3.98 2.83, 5.60 20/776 2.41 1.56, 3.74
Yes 100/3332 3.10 2.55, 3.77 32/3332 0.99 0.70, 1.40
Secondary analyses for IMT
ICA IMT quartiles
First 39/1023 3.63 2.65, 4.96 21/1023 1.95 1.27, 2.99
Second 28/1022 2.67 1.85, 3.87 13/1022 1.24 0.72, 2.14
Third 38/1021 3.80 2.76, 5.22 12/1021 1.20 0.68, 2.11
Fourth 27/1020 2.94 2.02, 4.29 6/1020 0.65 0.29, 1.45
CCA IMT quartiles
First 31/1054 2.80 1.97, 3.98 16/1054 1.44 0.88, 2.36
Second 34/1000 3.33 2.38, 4.66 11/1000 1.08 0.60, 1.94
Third 34/1047 3.30 2.36, 4.62 16/1047 1.55 0.95, 2.54
Fourth 33/986 3.74 2.66, 5.26 9/986 1.02 0.53, 1.96
ABI, ankle-brachial index; CCA, common carotid artery; ICA, internal carotid artery; IMT, intima-media thickness; ECG, electrocardiogram.
*80th percentile values: ICA IMT men 1.93 mm; ICA IMT women 1.68 mm; CCA IMT men 1.23 mm; CCA IMT women 1.14 mm.
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risk factors with VT incidence [17]. There was an association of
diabetes with VT incidence, but with longer follow-up here,
including only the older CHS participants, that association was
no longer present.
Taken together with a ﬁnding of no association of carotid
IMTwith risk of future VT in the ARIC (Atherosclerosis Risks
inCommunities) study (25), our studyprovidesprospectivedata
against a hypothesis that atherosclerosis is a risk factor for VT.
A few studies have evaluated VT as a predictor of subsequent
arterial events. For example, a 38-month observational study
evaluating the clinical course of patients with a ﬁrst episode of
idiopathic or secondary PE reported a higher incidence of
arterial events in patients with idiopathic than secondary PE
[26]. Another study reported a higher prevalence of coronary
artery calciﬁcation in patients with previous idiopathic VT than
in a control group [27]. In both of these studies patients withVT
were more likely than those free of VT to have classical arterial
disease risk factors, and since these are not generally considered
VT risk factors, results may be confounded.
Limitations of this study should be considered. There was a
relatively small number of VT events, however, given the high
prevalence of subclinical atherosclerosis in this older group, 133
VT events provided acceptable power for reliable analysis. We
did not adjust for treatments or high-risk periods for VT (e.g.
surgery) during follow-up, but most of these exposures would
not likely differ by subclinical atherosclerosis status, which was
not generally known by participants. It is possible that
exclusion of patients with prevalent clinical disease and
inclusion of relatively healthy elderly subjects might have
biased ﬁndings toward the null hypothesis. However, we
believe these design features strengthened our ability to study
associations of subclinical atherosclerosis and future VT
without confounding. The strengths of this study were the
wide array of subclinical disease measures and the prospective
design, which reduces many types of bias.
In summary, these data, which included assessment of
multiple arterial vascular beds using extensive non-invasive
testing, do not support a hypothesis that atherosclerosis is a risk
factor forVT in elderlymenandwomenwithout clinical arterial
disease. The ﬁndings would support the opposite conclusion;
that some types of atherosclerosis are associated with a lower
riskofVT.Asthiswasnotanticipated, further study is indicated.
Table 3 Hazard ratios (HR) of venous thromboembolism (VTE) according to subclinical disease status at baseline, 1989–2001
Characteristic
Hazard ratios of all VTE Hazard ratios of idiopathic VTE
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
ABI
‡ 0.9 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
< 0.9 1.33 0.73, 2.41 0.91 0.44, 1.91 1.13 0.40, 3.13 0.52 0.12, 2.17
ICA IMT (Sex speciﬁc*)
< 80th percentile 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
‡ 80th percentile 0.98 0.62, 1.54 0.73 0.43, 1.24 0.39 0.14, 1.09 0.27 0.08, 0.87
CCA IMT (Sex speciﬁc*)
< 80th percentile 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
‡ 80th percentile 1.19 0.78, 1.84 0.93 0.56, 1.54 0.77 0.35, 1.71 0.66 0.28, 1.59
Major ECG abnormalities
No 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Yes 0.74 0.46, 1.19 0.50 0.27, 0.92 0.74 0.35, 1.57 0.59 0.25, 1.40
Carotid plaque risk groups
Absent 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Intermediate 0.78 0.47, 1.28 0.73 0.43, 1.24 0.43 0.19, 0.97 0.42 0.19, 0.96
High 0.84 0.57, 1.24 0.65 0.42, 1.00 0.46 0.25, 0.83 0.34 0.18, 0.65
Any subclinical atherosclerosis
No 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Yes 0.79 0.53, 1.17 0.60 0.39, 0.91 0.42 0.24, 0.73 0.32 0.18, 0.59
Secondary analyses of carotid IMT
ICA IMT quartiles
First 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Second 0.74 0.46, 1.20 0.65 0.38, 1.10 0.64 0.32, 1.28 0.56 0.27, 1.17
Third 1.06 0.68, 1.65 0.93 0.58, 1.51 0.62 0.31, 1.26 0.52 0.24, 1.09
Fourth 0.82 0.50, 1.35 0.54 0.31, 0.95 0.34 0.14, 0.85 0.18 0.06, 0.55
CCA IMT quartiles
First 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Second 1.19 0.73, 1.94 0.90 0.53, 1.54 0.75 0.35, 1.61 0.60 0.26, 1.37
Third 1.19 0.73, 1.93 0.94 0.55, 1.59 1.09 0.54, 2.17 0.85 0.40, 1.80
Fourth 1.36 0.83, 2.22 0.95 0.55, 1.66 0.72 0.32, 1.64 0.57 0.23, 1.39
ABI, ankle-brachial index; CCA, common carotid artery; ICA, internal carotid artery; IMT, intima-media thickness; ECG, electrocardiogram.
*80th percentile values: ICA IMT men 1.93 mm; ICA IMT women 1.68 mm; CCA IMT men 1.23 mm; CCA IMT women 1.14 mm. Adjusted for age, sex,
race, factor VIII, and obesity status.
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